Novartis agreed to pay $2 billion upfront to acquire an experimental, pan‑mutant‑selective PI3Kα inhibitor from Synnovation Therapeutics, aiming to bolster or defend its breast‑cancer franchise. The asset targets PIK3CA‑driven tumors and is positioned as a next‑generation option with reported improved selectivity over older PI3K inhibitors. Novartis executives characterized the deal as a strategic bolt‑on to compete against rivals developing agents in the same pathway. For readers: PI3Kα inhibitors target a common oncogenic node—PIK3CA mutations—that confer growth signals in many breast tumors. The transaction underscores Big Pharma’s continued appetite for buying targeted oncology assets late in discovery to refresh pipelines and mitigate competitive risk. The upfront price highlights the premium attached to selective PI3Kα chemistry and clinical differentiation potential.